The tweet was deleted by the author.
But we saved everything 🙂.
Agenus has released updates on the execution of its ROBBIN Phase 3 clinical trial and developments in its BOT+BAL immunotherapy initiative targeting colorectal cancer.
The company also discussed the rationale for using immunotherapy before surgical intervention. These updates were shared during a recent stakeholder webcast, with a replay now available to interested parties.
View post on X Loading...